BG Medicine, Inc. announced that the ARCHITECT® Galectin-3 assay is now available. This automated blood test was cleared by the United States Food and Drug Administration (FDA) for use in conjunction with clinical evaluation as an aid in assessing the prognosis of patients diagnosed with chronic heart failure. The ARCHITECT Galectin-3 assay is performed using the Abbott ARCHITECT automated immunoassay analyzer and is being commercialized through an agreement between BG Medicine and Abbott.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.000001 USD | -.--% | -.--% | -.--% |
2016 | BG Medicine, Inc. Reports Earnings Results for the Full Year Ended December 31, 2015 | CI |
2016 | BG Medicine Announces Board Changes | CI |
1st Jan change | Capi. | |
---|---|---|
-.--% | 11 | |
-24.69% | 1.42B | |
-18.76% | 56.73M |
- Stock Market
- Equities
- BGMD Stock
- News BG Medicine, Inc.
- BG Medicine, Inc. Announces First Automated Test for Galectin-3 Now Available in U.S